Background and Purpose: Previous in vitro and in vivo studies of the effects of nitric oxide synthase inhibition in the central nervous system have yielded conflicting results concerning the role of nitric oxide in the events that lead to ischemic injury. In this study, we tested the hypothesis that preischemic inhibition of nitric oxide synthase increases infarct volume after reversible focal cerebral ischemia in rats.
Methods: NG-nitro-L-arginine methyl ester hydrochloride 15 mg/kg IV or an equivalent volume of saline was administered to adult Wistar rats 15 minutes before middle cerebral artery occlusion by the intraluminal suture method. After 2 hours of ischemia, the suture was withdrawn, and rats were allowed to survive for 3 days. Areas of infarction in 10 hematoxylin-eosin-stained sections were measured and used to determine infarct volume.
Results: Administration of NG-nitro-L-arginine methyl ester hydrochloride increased hemispheric infarct volume by 137% over control (60.9±30.5 to 144.3±19.6 mm3, P<.05; mean±SEM). Cortical and subcortical infarct volumes were increased by 176% (33.8±21.9 to 93.3±15.2 mm3, P<.05) and 103% (25.1±9.4 to 51.0±5.5 mm3, P<.03), respectively.
Conclusions: Nitric oxide synthase inhibition increases infarct volume and decreases the variability of the response to middle cerebral artery occlusion in Wistar rats, a strain that is normally resistant to focal cerebral ischemic injury owing to extensive collateralization. The mechanism of the deleterious effect of nitric oxide synthase inhibition likely involves a more severe degree of blood flow reduction during and after middle cerebral artery occlusion, primarily by preventing the vasodilatory response of collateral vessels to proximal middle cerebral artery occlusion. Maintenance of nitric oxide synthase activity during and after focal cerebral ischemia appears to minimize ischemic injury. (Stroke. 1993; 24:2023 -2029 On each postoperative day, the rats were weighed and assessed for right upper extremity motor deficit using the following scale: 0, normal; 1, asymmetry of extension or abduction of the right upper extremity when lifted by the tail; and 2, circling to the right during locomotion. After a 3-day survival, rats were reanesthetized and transcardially perfused with 0.9% saline at 140 cm water pressure for 2 minutes, followed by fixation with formaldehyde 37.5%/acetic acid/methanol (1:1:8) for 5 minutes. After the head had been in fixative for 24 hours, the brain was removed and processed for paraffin embedding. Ten-micron-thick sections were cut in the coronal plane and stained with hematoxylin and eosin. The areas of infarction at 10 levels throughout the brain were traced and measured, and the volume of infarction was calculated by numerical integration using a personal computer software program by an investigator who was blinded to the treatment group (J.W.K.). The areas of infarction included pancellular necrosis as well as dense areas of eosinophilic, shrunken neurons along the edges of the infarct.
Physiological measurements were made in a parallel group of seven rats receiving L-NAME 15 mg/kg (n=3) or an equivalent volume of 0.9% saline (n=4) 15 minutes before a 2-hour period of MCA occlusion. The anesthetic management and the method of MCA occlusion were exactly as described above. MAP and heart rate were measured via an indwelling femoral arterial transducer (model P23XL; Viggo-Spectramed, Inc, Oxnard, Calif) and recorded continuously (model RS3400; Gould Mean right upper extremity motor deficit scores were significantly higher in L-NAME-treated rats compared with controls on each day after ischemia (Table 2 ). In addition, body weight decreased significantly in L-NAME-treated rats, whereas it did not change in controls during the survival period (Table 2) .
Compared with controls, L-NAME-treated rats developed larger infarct volumes that were more consistent in size in the total cerebral hemisphere (144. Fig 1) . These represent increases over saline-treated rats of 137%, 176%, and 103%, respectively. L-NAME increased infarct volume to the greatest extent in the cortex. In controls, infarct volume was more variable in the cortex than in the subcortex.
catheter connected to a precalibrated Statham pressure Figs 2 through 4 illustrate the rostrocaudal distribution of infarct areas in the two groups. Four of 8 L-NAMEtreated rats had small, sometimes multiple intraparenchymal hemorrhages (3-in striatum, 1-in cortex), whereas only 1 of 7 saline-treated rats had a striatal hemorrhage. In addition, unilateral CA1 hippocampal necrosis was seen in 2 L-NAME-treated and 0 salinetreated rats. Discussion This study showed that L-NAME 15 mg/kg, when given before reversible MCA occlusion, increases infarct volume in spontaneously breathing, conscious Wistar rats. These findings are in agreement with those of Yamamoto et al,5 who administered N-omega-nitro-L-arginine (NNA) 2.4 mg/kg over 1 hour to spontane-L-NAME, NG-nitro-L-arginine methyl ester hydrochloride; NM, not ously hypertensive rats immediately after permanent occlusion of the MCA. In their study, NO synthase inhibition increased infarct volume by 32%, an effect that was completely prevented by the coadministration of the nitric oxide precursor L-arginine.1112 Morikawa et a16 also found that L-arginine decreased infarct volume after permanent MCA occlusion in spontaneously hypertensive rats. In contrast, Dawson et a113 administered L-NAME 30 mg/kg 30 minutes before and 30 minutes after permanent MCA occlusion in Sprague-Dawley rats and found no difference in the volume of ischemic damage; however, these investigators measured injury after only 4 hours of ischemia, which may not have been long enough to allow for the full development of infarction. In another study in which systemic variables such 10 induced vascular relaxation would further reduce blood flow to the ischemic tissue. The effects of L-NAME in this study may have been due to a combination of NO synthase inhibition and muscarinic receptor blockade.
Second, rats in this study were allowed to awaken immediately after MCA occlusion, thereby minimizing the cumulative dose of anesthetic. The volatile anesthetics have been shown to inhibit NO synthase, '8-20 and perhaps this accounts for the smaller difference in infarct volumes between nitro-arginine-treated and placebo-treated rats in previous studies. Dawson et al '3 maintained anesthesia with halothane 0.75% to 1.0% in a mixture of 70% nitrous oxide and 30% oxygen. Before MCA occlusion, MAP was approximately 82 mm Hg and increased to only 95 mm Hg after L-NAME 30 mg/kg. These blood pressures are clearly in the hypotensive range and are consistent with a cumulative effect of halothane on systemic vascular resistance.
Third, we studied the effect of NO synthase inhibition in a model of reversible focal ischemia. In this setting, one would expect NO synthase inhibition to delay or prevent the reestablishment of blood flow to ischemic areas. This has been demonstrated by Prado et al,8 who found that L-NAME 30 mg/kg given before 20 minutes of bilateral carotid artery occlusion attenuated early hyperemia and severely depressed cortical CBF during recirculation. However, the presence of intraparenchymal hemorrhages in half of the L-NAME-treated rats It is interesting that L-NAME was associated with a lower Paco2 early after MCA occlusion ( .m anterior choroidal artery, which supplies the anterior hippocampus, usually originates from the internal carotid artery posterior to the origin of the MCA. Injury to the endothelial lining of the intemal carotid artery at or before the anterior choroidal artery could be a source of thromboemboli.
On the other hand, NO synthase inhibition in the setting of reversible MCA occlusion might be expected to decrease reperfusion injury mediated by free radical species. Hydroxyl radical production is believed to increase in the presence of NO during reoxygenation of ischemic tissue. [26] [27] [28] In support of this theory, myocardial reperfusion injury was markedly reduced in piglets receiving L-NAME 4 mg/kg, protection that was lost by the addition of L-arginine. 28 According to the literature on the pathophysiology of NO in the central nervous system, NO has paradoxical effects in the setting of brain ischemia. In vitro studies of "brain cell" cultures, "pure" neuronal cultures, and brain slices clearly show that NO, produced either directly from sodium nitroprusside4 or indirectly via activation of N-methyl-D-aspartate receptors,2,4 injures brain cells. On the other hand, none of the in vivo studies in which systemic variables were measured and controlled support the hypothesis that NO synthase inhibition protects the brain from ischemic injury.56,13 Indeed, we demonstrated a marked increase in ischemic damage in the presence of NO synthase inhibition. Based on the present study and other in vivo studies, 5, 6 we conclude that the effects of NO in the artificial microenvironment of the tissue-culture setting do not correlate with its effects in the intact living brain, where the spatial arrangement of individual types of cells, the supply of substrate, and the removal of toxins are vastly different. When taken from their natural microenvironment in the brain and grown in tissue culture, neurons may synthesize NO that cannot be buffered or absorbed by neighboring nonneuronal cells such as smooth muscle cells, astrocytes, and endothelial cells, in which NO production and subsequent activation of guanylate cyclase may have a beneficial effect during ischemia.
In summary, this study clearly demonstrated that L-NAME 15 mg/kg increased functional and histopathologic damage after 2 hours of reversible MCA occlusion in rats. Maintenance of NO synthase activity appears to improve outcome after focal cerebral ischemia/reperfusion injury, particularly in animal strains that have greater cerebral vasodilatory reserve.
